Skip to main content

Clinical Evidence in Gynaeoncology: Sources and Application

  • 218 Accesses

Abstract

Clinical practice is evolving fast with technological advances, improved understanding of cancer biology and clinical complexity with an aging population. While new research adds to the pool of evidence, each clinician ought to use the current best evidence to inform care decisions- the basis of evidence-based medicine (EBM).

Acknowledging the skills and training required to practice EBM is crucial. In this chapter, we explore the components of evidence-based practice based on the five-step model proposed in the Sicily statement on evidence-based practice, with selected examples relevant to gynaeoncologists. In addition, we suggest relevant resources to help embed EBM into everyday practice to complement the development of clinical and technical skills.

We hope to inspire and equip you to incorporate the principles of EBM in your day-to-day practice, with the common goal to improve the clinical care of our patients.

Keywords

  • Evidence-based medicine
  • Clinical trial
  • Medical education
  • Research
  • Critical appraisal
  • Clinical audit

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-94110-9_5
  • Chapter length: 15 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   149.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-94110-9
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   199.99
Price excludes VAT (USA)
Fig. 5.1
Fig. 5.2

References

  1. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822–32.

    PubMed  CrossRef  Google Scholar 

  2. McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, et al. No surgical innovation without evaluation: the IDEAL recommendations. Lancet. 2009;374(9695):1105–12.

    PubMed  CrossRef  Google Scholar 

  3. Dawes M, Summerskill W, Glasziou P, Cartabellotta A, Martin J, Hopayian K, et al. Sicily statement on evidence-based practice. BMC Med Educ. 2005;5(1):1.

    PubMed  PubMed Central  CrossRef  Google Scholar 

  4. Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14(1):579.

    PubMed  PubMed Central  CrossRef  Google Scholar 

  5. Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379(20):1895–904.

    PubMed  CrossRef  Google Scholar 

  6. Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evid Based Med. 2016;21(4):125.

    PubMed  PubMed Central  CrossRef  Google Scholar 

  7. Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction. BMJ. 2016;353:i2016.

    PubMed  CrossRef  Google Scholar 

  8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

    PubMed  PubMed Central  CrossRef  Google Scholar 

  9. Alper BS, Haynes RB. EBHC pyramid 5.0 for accessing preappraised evidence and guidance. Evid Based Med. 2016;21(4):123.

    PubMed  CrossRef  Google Scholar 

  10. Melamed A, Margul DJ, Chen L, Keating NL, del Carmen MG, Yang J, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J Med. 2018;379(20):1905–14.

    PubMed  PubMed Central  CrossRef  Google Scholar 

  11. Hillemanns P, Hertel H, Klapdor R. Radical hysterectomy for early cervical cancer: what shall we do after the LACC trial? Arch Gynecol Obstet. 2020;302(2):289–92.

    PubMed  CrossRef  Google Scholar 

  12. AOCT Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. BMJ. 1991;303(6807):884–93.

    CrossRef  Google Scholar 

  13. TOCM-A Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The ovarian cancer meta-analysis project. J Clin Oncol. 1991;9(9):1668–74.

    CrossRef  Google Scholar 

  14. International Collaborative Ovarian Neoplasm Collaborators. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003;95(2):125–32.

    CrossRef  Google Scholar 

  15. ICON Group. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet. 1998;352(9140):1571–6.

    CrossRef  Google Scholar 

  16. ICON Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360(9332):505–15.

    CrossRef  Google Scholar 

  17. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099–106.

    CAS  PubMed  CrossRef  Google Scholar 

  18. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer InterGroup. J Clin Oncol. 2009;27(9):1419–25.

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  19. Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387(10023):1066–74.

    CAS  PubMed  CrossRef  Google Scholar 

  20. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.

    CAS  PubMed  CrossRef  Google Scholar 

  21. Clamp AR, James EC, McNeish IA, Dean A, Kim J-W, O’Donnell DM, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019;394(10214):2084–95.

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  22. Elyashiv O, Ledermann J, Parmar G, Farrelly L, Counsell N, Feeney A, et al. ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. Int J Gynecol Cancer. 2021;31(1):134.

    PubMed  CrossRef  Google Scholar 

  23. Ghersi D, Parmar MKB, Stewart LA, Marsoni S, Williams CJ. Early ovarian cancer and the Icon trials. Eur J Cancer. 1992;28(6):1297.

    CrossRef  Google Scholar 

  24. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol. 1999;10:S87–92.

    CrossRef  Google Scholar 

  25. Harter P, Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol. 2006;13(12):1702–10.

    PubMed  CrossRef  Google Scholar 

  26. Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for Operability of recurrent ovarian cancer: the multicenter Intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289–95. https://doi.org/10.1097/IGC.0b013e31820aaafd.

    CrossRef  PubMed  Google Scholar 

  27. Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, et al. A risk model for secondary Cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19(2):597–604.

    PubMed  CrossRef  Google Scholar 

  28. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical Cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929–39.

    PubMed  PubMed Central  CrossRef  Google Scholar 

  29. Du Bois A, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol. 2020;38(15_suppl):6000.

    CrossRef  Google Scholar 

  30. Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):439–49.

    CAS  PubMed  CrossRef  Google Scholar 

  31. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106(9):1933–9.

    PubMed  CrossRef  Google Scholar 

  32. Fort DG, Herr TM, Shaw PL, Gutzman KE, Starren JB. Mapping the evolving definitions of translational research. J Clin Transl Sci. 2017;1(1):60–6.

    PubMed  PubMed Central  CrossRef  Google Scholar 

  33. Hausen HZ, Meinhof W, Scheiber W, Bornkamm GW. Attempts to detect virus-specific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virus. Int J Cancer. 1974;13(5):650–6.

    PubMed  CrossRef  Google Scholar 

  34. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3(5):1151–7.

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  35. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985;314(6006):111–4.

    CAS  PubMed  CrossRef  Google Scholar 

  36. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.

    CAS  PubMed  CrossRef  Google Scholar 

  37. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.

    CAS  PubMed  CrossRef  Google Scholar 

  38. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.

    CAS  PubMed  CrossRef  Google Scholar 

  39. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579–89.

    CAS  PubMed  CrossRef  Google Scholar 

  40. Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199–203.

    CAS  PubMed  CrossRef  Google Scholar 

  41. Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, et al. A phase I–II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;23(15):4095.

    CAS  PubMed  CrossRef  Google Scholar 

  42. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.

    CAS  PubMed  CrossRef  Google Scholar 

  43. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61.

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  44. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84.

    CAS  PubMed  CrossRef  Google Scholar 

  45. Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620–31.

    CAS  PubMed  CrossRef  Google Scholar 

  46. Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–505.

    CAS  PubMed  CrossRef  Google Scholar 

  47. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–28.

    CAS  PubMed  CrossRef  Google Scholar 

  48. González-Martín A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–402.

    PubMed  CrossRef  Google Scholar 

  49. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, et al. Human papillomavirus testing in primary cervical screening. Lancet. 1995;345(8964):1533–6.

    CAS  PubMed  CrossRef  Google Scholar 

  50. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, et al. HPV testing in primary screening of older women. Br J Cancer. 1999;81(3):554–8.

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  51. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362(9399):1871–6.

    CAS  PubMed  CrossRef  Google Scholar 

  52. Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PPL, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017;8(8):CD008587.

    PubMed  Google Scholar 

  53. Committee UNS. Consultation on modifying the NHS Cervical Screening Programmes in the four UK nations The United Kingdom: UK National Screening Committee; 2019 [cited 2021 4 April]. Available from: https://legacyscreening.phe.org.uk/cervicalcancer.

  54. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143.

    PubMed  PubMed Central  CrossRef  Google Scholar 

  55. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). The Cochrane Collaboration 2021.

    Google Scholar 

  56. Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.

    CrossRef  Google Scholar 

  57. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.

    PubMed  CrossRef  Google Scholar 

  58. Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials. 2007;8(1):39.

    PubMed  PubMed Central  CrossRef  Google Scholar 

  59. National Cancer Registration and Analysis Service (NCRAS). Gynaecological Cancer Hub. The United Kingdom. 2020 [Last access: 14 April 2021]. Available from: http://www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/gynaecological_cancer/gynaecological_cancer_hub/

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Elaine Leung .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Leung, E., Sundar, S. (2022). Clinical Evidence in Gynaeoncology: Sources and Application. In: Singh, K., Gupta, B. (eds) Gynecological Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-94110-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-94110-9_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-94109-3

  • Online ISBN: 978-3-030-94110-9

  • eBook Packages: MedicineMedicine (R0)